Mirum Pharmaceuticals director plans $1.94M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mirum Pharmaceuticals, Inc. (MIRM) officer and director Christopher Peetz reports a planned sale of 20,000 common shares, with an approximate sale date of November 20, 2026, and an aggregate market value of $1,940,100. The shares are listed as acquired from the issuer through a cash-paid stock-option exercise on November 20, 2026; the listed Rule 10b5-1 plan-adoption or instruction date is March 2, 2026. Peetz also lists sales of 20,000 shares for $1,800,000 gross proceeds on November 4, 2026, and 30,000 shares for $2,960,319 on September 1, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Stock Options Exercise financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.